- Home
- LWLG vs KLRS Comparison
LWLG vs KLRS Comparison
Compare LWLG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- KLRS
- Stock Information
- Founded
- LWLG 1991
- KLRS 2019
- Country
- LWLG United States
- KLRS United States
- Employees
- LWLG N/A
- KLRS N/A
- Industry
- LWLG Containers/Packaging
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LWLG Industrials
- KLRS Health Care
- Exchange
- LWLG Nasdaq
- KLRS Nasdaq
- Market Cap
- LWLG 126.0M
- KLRS 129.0M
- IPO Year
- LWLG N/A
- KLRS N/A
- Fundamental
- Price
- LWLG $0.98
- KLRS $2.90
- Analyst Decision
- LWLG
- KLRS Buy
- Analyst Count
- LWLG 0
- KLRS 1
- Target Price
- LWLG N/A
- KLRS N/A
- AVG Volume (30 Days)
- LWLG 951.2K
- KLRS 52.4K
- Earning Date
- LWLG 05-13-2025
- KLRS 05-14-2025
- Dividend Yield
- LWLG N/A
- KLRS N/A
- EPS Growth
- LWLG N/A
- KLRS N/A
- EPS
- LWLG N/A
- KLRS N/A
- Revenue
- LWLG $88,105.00
- KLRS N/A
- Revenue This Year
- LWLG N/A
- KLRS N/A
- Revenue Next Year
- LWLG N/A
- KLRS N/A
- P/E Ratio
- LWLG N/A
- KLRS N/A
- Revenue Growth
- LWLG 24.23
- KLRS N/A
- 52 Week Low
- LWLG $0.79
- KLRS $2.65
- 52 Week High
- LWLG $4.23
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- LWLG 46.81
- KLRS N/A
- Support Level
- LWLG $1.00
- KLRS N/A
- Resistance Level
- LWLG $1.54
- KLRS N/A
- Average True Range (ATR)
- LWLG 0.13
- KLRS 0.00
- MACD
- LWLG -0.01
- KLRS 0.00
- Stochastic Oscillator
- LWLG 9.94
- KLRS 0.00
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.